secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092654
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya enters cardiovascular gene target collaboration with Alnylam; up to $10M upfront, $1.13B milestones
--------------------------------------------------------------------------------

- Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.
- Tenaya receives up to $10M upfront payment within 30 days, subject to reductions for targets not advanced.
- Tenaya eligible for up to $1.13B in development, regulatory, and sales milestones for company-nominated targets.
- Alnylam gets exclusive worldwide license; may unilaterally terminate for any reason. Tenaya restricted on certain targets.
- Alnylam reimburses Tenaya for FTEs and out-of-pocket costs per research budget; each party covers own costs otherwise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/0001193125-26-092654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/tnya-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer